Terumo Corporation risk profile
35 Normal where most of the sector sits
Measured 1 September 2026 from TUO0's filed statements. Recomputed nightly.
35 (Normal), driven by Competitive position at 43, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 40 | Elevated | Stable | Average daily turnover — $1.2K |
| Operating pressure | 39 | Normal | Easing | Costs outgrowing revenue — -0.5 percentage points |
| Cash conversion | 28 | Normal | Worsening | Capital spending against operating cash — 0.44x |
| Leverage and coverage | 12 | Contained | Worsening | Current ratio — 1.59x |
| Competitive position | 43 | Elevated | Stable | Operating-margin gap against peers — +2.1 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for Terumo Corporation